These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15728126)

  • 1. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
    Zhu K; Gerbino E; Beaupre DM; Mackley PA; Muro-Cacho C; Beam C; Hamilton AD; Lichtenheld MG; Kerr WG; Dalton W; Alsina M; Sebti SM
    Blood; 2005 Jun; 105(12):4759-66. PubMed ID: 15728126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.
    Izbicka E; Campos D; Carrizales G; Patnaik A
    Anticancer Res; 2005; 25(5):3215-23. PubMed ID: 16101130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
    Le Gouill S; Pellat-Deceunynck C; Harousseau JL; Rapp MJ; Robillard N; Bataille R; Amiot M
    Leukemia; 2002 Sep; 16(9):1664-7. PubMed ID: 12200678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.
    Rolland D; Camara-Clayette V; Barbarat A; Salles G; Coiffier B; Ribrag V; Thieblemont C
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):855-63. PubMed ID: 17639395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.
    Ochiai N; Uchida R; Fuchida S; Okano A; Okamoto M; Ashihara E; Inaba T; Fujita N; Matsubara H; Shimazaki C
    Blood; 2003 Nov; 102(9):3349-53. PubMed ID: 12842991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy.
    Cornelissen B; Lahorte C; Kersemans V; Capriotti G; Bonanno E; Signore A; Van de Wiele C; Dierckx RA; Slegers G
    Nucl Med Biol; 2005 Apr; 32(3):233-9. PubMed ID: 15820758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.
    Beaupre DM; McCafferty-Grad J; Bahlis NJ; Boise LH; Lichtenheld MG
    Leuk Lymphoma; 2003 Dec; 44(12):2123-34. PubMed ID: 14959858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
    Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
    Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
    Santucci R; Mackley PA; Sebti S; Alsina M
    Cancer Control; 2003; 10(5):384-7. PubMed ID: 14581893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
    Martin LA; Head JE; Pancholi S; Salter J; Quinn E; Detre S; Kaye S; Howes A; Dowsett M; Johnston SR
    Mol Cancer Ther; 2007 Sep; 6(9):2458-67. PubMed ID: 17876043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis.
    Gervasoni JE; Hindenburg AA; Vezeridis MP; Schulze S; Wanebo HJ; Mehta S
    Anticancer Res; 2004; 24(5A):2617-26. PubMed ID: 15517865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
    Qiu Y; Liu X; Zou W; Yue P; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4973-80. PubMed ID: 17510428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
    Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
    Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
    Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
    Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
    Siegel-Lakhai WS; Crul M; Zhang S; Sparidans RW; Pluim D; Howes A; Solanki B; Beijnen JH; Schellens JH
    Br J Cancer; 2005 Nov; 93(11):1222-9. PubMed ID: 16251868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
    Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
    Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
    Smith V; Rowlands MG; Barrie E; Workman P; Kelland LR
    Clin Cancer Res; 2002 Jun; 8(6):2002-9. PubMed ID: 12060646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.